Our findings suggest that dual targeting of eIF4F-mediated translation initiation and XPO1-mediated nuclear export has potential to combat high-risk NB, particularly in patients with MYCN-amplified metastatic tumors, who currently have limited treatment options. Here, XPO1 is linked to neuroblastoma.